Halozyme Therapeutics (NASDAQ:HALO) Sets New 52-Week High – Here’s What Happened

Halozyme Therapeutics, Inc. (NASDAQ:HALO) shares reached a new 52-week high during trading on Wednesday. The stock traded as high as $125.10 and last traded at $124.37, with a volume of 2,149,026 shares. The stock had previously closed at $122.50.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on HALO. Zacks Research upgraded shares of Halozyme Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 13th. Wall Street Zen upgraded Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 8th. JPMorgan Chase & Co. upped their target price on shares of Halozyme Therapeutics from $70.00 to $78.00 and gave the stock a “neutral” rating in a research note on Thursday, October 8th. Citizens Jmp boosted their target price on shares of Halozyme Therapeutics from $92.00 to $93.00 and gave the company a “market outperform” rating in a research note on Friday, August 7th. Finally, Weiss Ratings raised Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Monday, August 31st. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Halozyme Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $99.55.

Halozyme Therapeutics Price Performance

The company has a market capitalization of $14.14 billion, a PE ratio of 25.32, a price-to-earnings-growth ratio of 0.47 and a beta of 0.88. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50. The stock’s 50-day moving average is $110.83 and its two-hundred day moving average is $86.75.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, topping the consensus estimate of $1.79 by $0.49. The company had revenue of $481.00 million for the quarter, compared to the consensus estimate of $402.28 million. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The firm’s revenue was up 47.7% compared to the same quarter last year. During the same quarter last year, the firm posted $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, equities analysts predict that Halozyme Therapeutics, Inc. will post 8.31 EPS for the current year.

Insiders Place Their Bets

In other news, Director Bernadette Connaughton sold 1,626 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $102.80, for a total value of $167,152.80. Following the completion of the sale, the director owned 40,418 shares of the company’s stock, valued at $4,154,970.40. This trade represents a 3.87% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Matthew L. Posard sold 18,996 shares of the business’s stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $107.74, for a total value of $2,046,629.04. Following the sale, the director owned 58,839 shares in the company, valued at $6,339,313.86. The trade was a 24.41% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 125,852 shares of company stock worth $13,538,046. 2.50% of the stock is owned by corporate insiders.

Institutional Trading of Halozyme Therapeutics

Large investors have recently bought and sold shares of the stock. Fifth Third Wealth Advisors LLC increased its position in shares of Halozyme Therapeutics by 3.5% in the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 4,515 shares of the biopharmaceutical company’s stock valued at $498,000 after acquiring an additional 151 shares during the period. Sterling Capital Management LLC raised its stake in Halozyme Therapeutics by 570.8% in the 3rd quarter. Sterling Capital Management LLC now owns 5,199 shares of the biopharmaceutical company’s stock worth $574,000 after acquiring an additional 4,424 shares during the last quarter. James Investment Research Inc. lifted its position in Halozyme Therapeutics by 10.8% during the 3rd quarter. James Investment Research Inc. now owns 29,436 shares of the biopharmaceutical company’s stock worth $3,250,000 after acquiring an additional 2,858 shares during the period. Inspire Investing LLC acquired a new stake in Halozyme Therapeutics during the 3rd quarter worth about $3,129,000. Finally, Root Financial Partners LLC purchased a new stake in Halozyme Therapeutics during the 3rd quarter valued at about $82,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that can improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses a proprietary recombinant human hyaluronidase enzyme to facilitate the subcutaneous delivery of biologic drugs and other injectable therapies that may otherwise require intravenous infusion.

Halozyme licenses its technologies to pharmaceutical and biotechnology companies, which use them in a range of marketed and investigational products.